Wednesday, February 04, 2026 7:25:04 PM
Prv is fantastic
Recent OSTX News
- OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World • Newsfile • 05/29/2026 11:20:00 AM
- OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences • Newsfile • 05/26/2026 11:40:00 AM
- OS Therapies Reports First Quarter 2026 Financials and Provides Business Update • Newsfile • 05/18/2026 10:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/18/2026 10:02:31 AM
- Form 5/A - Annual statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 05/15/2026 10:30:02 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2026 08:15:58 PM
- OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 • Newsfile • 05/15/2026 08:05:00 PM
- OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor • Newsfile • 05/14/2026 11:30:00 AM
- Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) • Newsfile • 05/12/2026 06:35:00 PM
- OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma • Newsfile • 04/30/2026 10:00:00 AM
- OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET • Newsfile • 04/27/2026 08:01:00 PM
- OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes • Newsfile • 04/16/2026 11:20:00 AM
- OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor • Newsfile • 04/13/2026 10:00:00 AM
- OS Therapies Appoints Craig Eagle, MD as Strategic Advisor • Newsfile • 04/08/2026 03:38:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 09:25:09 PM
- OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors • Newsfile • 04/02/2026 09:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/02/2026 09:00:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:20:28 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 03/31/2026 08:08:42 PM
- OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update • Newsfile • 03/31/2026 11:40:00 AM
- OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma • Newsfile • 03/27/2026 10:00:00 AM
- OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma • Newsfile • 03/25/2026 10:00:00 AM
- The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology • GlobeNewswire Inc. • 03/19/2026 03:00:00 PM
- OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting • Newsfile • 03/09/2026 11:40:00 AM
